PerpEquities

Equity · Healthcare

Boston Scientific Corporation (BSX) perpetual futures

BSX perpetual futures on 2 crypto exchanges – live perp price vs the stock, funding rate, open interest and where to trade BSXUSDT.

Boston Scientific is a global medical technology company that designs and sells innovative medical devices for interventional specialties, including cardiology, rhythm management, neurology, and surgery.

$42.020.0%NYSE closed
Open in terminal

Price chart

 

Use the left and right arrow keys to inspect points on the chart.

venue perp mark · MEXC (BSX/USDT)
Auto: highest-volume live perp venueOpen in TradingView

Trading data

Perpetual market activity

2/3 live markets
Venues
2
Live markets
2/3
24h volume
$103.3K
Open interest
$43.1K
Best liquidity
$5K
Gate.io
Tightest spread
+166.6 bps
Gate.io
Highest volume
$103.3K
MEXC
Settlement mix
USDT · 3/3
Perp/spot vol.
0.00x
Spot volume $639.7M
OI / float
0.00%
Float $60.5B
Spot performance
1D-2.35%
5D-5.94%
1M-5.68%
6M-26.54%
YTD-55.97%
1Y-56.67%

Venue matrix

3 markets

Some venue links are sponsored. We may receive a commission, and eligible users may occasionally receive trading-fee discounts, at no additional cost to you.

Trade
MEXCTradeBSX/USDTTrading$42.46+21.9% APR
+0.020% every 8h
+310.9 bps$0$103.3K$37.4KUSDT20x
Gate.ioTradeBSX/USDTTrading$42.020.0% APR
0.000% every 8h
+166.6 bps$5K$0$5.7KUSDT20x
BingXTradeBSX-USDTWatchlist------USDT-

Tradability

Execution quality

Entry cost and depth per venue at $1k–$100k

No sufficient depth · 0 of 2 venues absorb $10k

No fresh book data: Gate.io, MEXC

Taker execution estimate incl. approx. fees - maker fills are not guaranteed.

Best venues for this underlying

Best liquidity

BSX

Tightest spread

BSX

Highest volume

BSX

Funding history

Stored venue snapshots by market

Company financials

Financials at a glance

Last report Q3 '26 · filed 2026-11-02 · next report 2027-02-03 · Updated 4h ago
All financials →

Valuation & key figures

Market cap
$60.8B
Updated 4h ago
Revenue
$21.1B
Trailing 12 months
Revenue growth
+4%
FY2026 consensus
Profit margin
16.6%
Net income / revenue, TTM
P/E
17.8×
Forward 13.3× (FY2026)
P/S
2.9×
Price / sales, TTM
Peer P/E
35.0×
Similar listed perps
EV / EBITDA
13.6×
TTM
Free cash flow
$3.33B
Trailing 12 months
Net income
$3.49B
Trailing 12 months
Revenue estimate
$21B
FY2026 consensus
Earnings
2027-02-03
Revenue est. $5.18B · Updated 4h ago
Dividend
–
No dividend
Revenue (TTM)$21.1B+8.9% vs a year agoLast 4 quarters; bars = each quarter
Operating margin (TTM)21.0%+3.7 pp vs a year agoOperating income $4.44B
Net income (TTM)$3.49B+25.2% vs a year agoAfter tax, incl. non-operating gains
Free cash flow (TTM)$3.33B-12.9% vs a year agoCapex $903M
Diluted EPS (TTM)$2.36+26.8% vs a year agoSum of the last 4 quarters
Net cash-$11.3B-5.3% vs a year agoCash + short-term investments - debt
  • Last report (2026-10-28): revenue beat by 1.0%, EPS in lineRevenue $5.14B vs $5.09B expected (+1.0%); EPS $0.73 vs $0.73 (+0.4%).
  • Revenue growth slowing: 1.4% year on yearQ3 '26 revenue $5.14B, against an average of 13.8% over the four quarters before.
  • Operating margin 21.0% (TTM), +3.7 pp on a year agoOperating income grew 32.2% while revenue grew 8.9%.
  • 21.3% of pre-tax profit is eaten by non-operating lossesPre-tax income $3.66B vs operating income $4.44B (TTM). Losses on equity stakes and other one-off items cut net income and EPS - operating income is the cleaner measure of the business.

Revenue, operating income and growth

quarterly

Revenue by business line

Q3 '26
LineRevenuey/yShare of listed
Cardiovascular$3.41B+1.9%66.3%
MedSurg$1.73B+0.6%33.7%
In the full financialsIncome statement, balance sheet and cash flow (12 quarters / 10 years) · margins and cost structure · capital allocation and buybacks · valuation against the 5-year range · analyst estimates · all 346 lines Boston Scientific Corporation reported to the SEC

Next catalyst

Catalysts

Earnings
2027-02-03
Revenue est. $5.18B · Updated 4h ago

No unusual perp activity right now.

Research data

Analysts, filings and peer context

Estimates

6
DateEPS estimateRevenue estimateGrowthAnalysts
FY 20263.16$21B+4%16
FY 20273.12$20.8B-1%16
FY 20283.35$21.9B+5%9
FY 20293.65$23.2B+6%3
FY 20304.01$25.6B+10%3
Q1 20270.75$5.1B-3%10
Source: FMP · Consensus

Company events

6
2027-02-03EarningsActual - / Estimate 0.78-
2026-10-28Earnings · Before market openActual 0.73 / Estimate 0.727Beat
2026-07-29EarningsActual 0.86 / Estimate 0.835Beat
2026-04-22EarningsActual 0.8 / Estimate 0.788Beat
2026-02-04EarningsActual 0.8 / Estimate 0.781Beat
2025-10-22EarningsActual 0.75 / Estimate 0.714Beat

Peer comparison

Similar listed perps

Company data

Company intelligence

Updated: Nov 22, 2026, 10:53 AM UTC

Company profile

Sector
Healthcare
Industry
Medical - Devices
Chief executive
Michael F. Mahoney
Employees
59,000
IPO date
May 19, 1992
Country
US
Exchange
New York Stock Exchange
Website
Altman Z-scorei3.06
Piotroski scorei8/9
Overall ratingiA-
Owner earningsi$1.37B$0.92 per share
ESG risk ratingiBIndustry rank: 15/170

Rating factors

Return on equityi
4/5
Return on assetsi
5/5
Debt to equityi
2/5
Price to earningsi
2/5
Price to booki
3/5
Market cap history
$60.85B-16.0%Aug 2026 – Nov 2026
$60.85B$66.63B$72.42BHigh: $72.42B · 2026-08-24Latest: $60.85B · 2026-11-20Aug 2026Sep 2026Oct 2026Nov 2026
Latest: $60.85B · 2026-11-20High: $72.42B · 2026-08-24Low: $60.85B · 2026-11-20
M&A filings
Largest fund holders
FundWeightShares held
VTI0.1%47.2M
VOO0.11%39.5M
VPMAX1.37%30.9M
FXAIX0.11%20.7M
IVV0.1%18.5M
SPY0.1%17.4M
S5SD.L0.16%11.6M
VGHAX1.24%11.3M
XLV1.03%10.1M
VECP.S0.19%10M
VUG0.11%9.1M
VHCAX1.15%8.8M

Analyst track record

How the analysts covering BSX have done: ratings, price-target accuracy and the measured reaction after their calls.

12 months3 years
Ratings248644
Analysts3236
Buy / hold / sell229 / 19 / 0605 / 39 / 0
Upgrades / downgrades / initiations1 / 8 / 34 / 10 / 6
Price targets hit / missed0 / 230 (0%)0 / 590 (0%)
Avg. return after a rating (TipRanks)-44.1%-51.1%
Best / worst call-2.3% / -68.4%-2.3% / -69.3%

After buy calls on this stock: median 21-day move +1.4% vs S&P 500 -1.8% (n = 640)

Most accurate on this stock

Share of an analyst's price targets on this stock that the price reached within 12 months (our measurement over the last 3 years, at least 8 targets). It describes past calls, not the odds of the current one.

  1. Patrick WoodUBS71% hit rate on this stock · 17 targets measuredBuytarget $57.00Oct 29, 2026
  2. Matthew O'BrienPiper Sandler69% hit rate on this stock · 16 targets measuredBuytarget $60.00Oct 14, 2026
  3. William PlovanicCanaccord Genuity68% hit rate on this stock · 19 targets measuredBuytarget $48.00Nov 3, 2026

Latest ratings

DateAnalystCallTarget
Nov 19, 2026Joanne WuenschCitiNov 19, 2026HoldReiterated$44.00↗
Nov 3, 2026William PlovanicCanaccord GenuityNov 3, 2026BuyMaintained$48.00↗
Nov 2, 2026David ToungArgus ResearchNov 2, 2026HoldMaintained–↗
Nov 2, 2026Robbie MarcusJ.P. MorganNov 2, 2026HoldMaintained–↗
Oct 30, 2026Travis SteedBank of America SecuritiesOct 30, 2026BuyReiterated$54.00↗
Consensus over the last 12 months buy hold sell avg. target month-end close
Monthly buy, hold and sell shares of analyst ratings with the average price target and the month-end close$40.00$60.00$80.00$100$120Dec 25 · Buy 24 · Hold 2 · Sell 0Dec 25Jan 26 · Buy 24 · Hold 1 · Sell 0Feb 26 · Buy 25 · Hold 1 · Sell 0Feb 26Mar 26 · Buy 24 · Hold 1 · Sell 0Apr 26 · Buy 28 · Hold 1 · Sell 0Apr 26May 26 · Buy 26 · Hold 3 · Sell 0Jun 26 · Buy 26 · Hold 3 · Sell 0Jun 26Jul 26 · Buy 26 · Hold 4 · Sell 0Aug 26 · Buy 25 · Hold 4 · Sell 0Aug 26Sep 26 · Buy 22 · Hold 4 · Sell 0Oct 26 · Buy 18 · Hold 10 · Sell 0Oct 26Nov 26 · Buy 18 · Hold 10 · Sell 0Dec 25 · avg. target $126Jan 26 · avg. target $124Feb 26 · avg. target $110Mar 26 · avg. target $104Apr 26 · avg. target $91.19May 26 · avg. target $86.46Jun 26 · avg. target $80.76Jul 26 · avg. target $67.89Aug 26 · avg. target $66.28Sep 26 · avg. target $61.83Oct 26 · avg. target $51.24Nov 26 · avg. target $51.46Dec 25 · month-end close $95.35Jan 26 · month-end close $93.53Feb 26 · month-end close $76.85Mar 26 · month-end close $62.75Apr 26 · month-end close $57.61May 26 · month-end close $48.31Jun 26 · month-end close $42.68Jul 26 · month-end close $46.73Aug 26 · month-end close $48.30Sep 26 · month-end close $43.65Oct 26 · month-end close $41.98Nov 26 · month-end close $42.00

Share of analysts per call each month (latest call per analyst within 180 days). Targets and closes in USD.

TipRanks data · computed Nov 20, 2026 · 248 ratings

Frequently asked questions

Where can I trade BSX perpetual futures?

Boston Scientific Corporation (BSX) perpetual futures trade on 2 crypto venues, including MEXC, Gate.io. PerpEquities compares them by live price, funding rate, open interest and liquidity.

Can I trade BSX around the clock?

Yes. Unlike the underlying stock, BSX perpetuals trade 24/7 — including weekends and outside regular market hours.

What is the funding rate on BSX perpetuals?

Right now the BSX perp funding rate is +11.0% annualized (venue median), ranging from 0.0% to +21.9% across 2 venues. A positive rate means longs pay shorts. PerpEquities shows the live rate and its history for every venue.

How does the BSX perp price compare to the Boston Scientific Corporation stock?

The venue-median BSX perp mark is $42.2 versus a reference stock price of $42, a basis of +0.5%. Perps follow the stock through an index price; the gap widens when funding or liquidity diverge between venues.

What is a BSX perpetual future?

A BSX perpetual is a derivative that tracks the price of Boston Scientific Corporation with no expiry date. It lets you take long or short exposure to Boston Scientific Corporation on crypto venues, around the clock.

What is BSXUSDT perpetual?

BSXUSDT is the symbol most crypto exchanges use for the Boston Scientific Corporation perpetual settled in USDT (Tether). It tracks the BSX share price through an index, trades 24/7 with leverage and never expires.

Embed this asset

BSX perpetuals · perpequities.comBSX perpetuals · perpequities.com
<a href="https://perpequities.com/stocks/bsx-perp"><img src="https://perpequities.com/badge/bsx-perp.svg" width="240" height="64" alt="BSX perpetuals · perpequities.com" loading="lazy"></a>

Next step

Stay on top of BSX perps

Signals with a track record

Analysts who hit 70%+ of their targets on the perps we track, congress buys over $500k, 13F positions over $5M, funding spreads that have paid for days. Every post shows the evidence. Free, no sign-up.

Join on Telegram

Weekly digest by email

The listings, funding and moves that matter for BSX — one email every Sunday.

Watchlist and alerts

Price and funding alerts for BSX, via push or Telegram.

Set an alert

Follow the live feed

Daily movers, new listings and funding extremes as they happen.

Follow on X